Analysis Tools
hematopoietic system
|
• post-pIPC treatment
|
|
• block in erythroblast development resulting in an increase at development stage R2 and a decrease in R4 population in spleen at 45 weeks post-piPC
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
|
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 45 weeks post-piPC treatment
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment
• increase in short term repopulating hematopoietic stem cells (ST-HSC) in bone marrow 45 weeks post-piPC treatment
|
|
• in transplantation experiments, pIpC-treated hematopoietic stem cells exhibit increased self-renewal compared with control cells
|
immune system
|
• post-pIPC treatment
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
mortality/aging
|
• 17.7% of mice treated with polyinosinicpolycytidylic acid (pIpC) at 4 weeks of life die by 50 weeks of age
|
growth/size/body
|
• post-pIPC treatment
|
